Identifying t cell profiles that associate with clinical response to anti-PD-1 treatment in non-small cell lung carcinoma (NSCLC) patients.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e21239
Abstract: e21239Background: Checkpoint inhibitors, such as the PD-1 antibody nivolumab, have been approved for the treatment of several cancer types, including NSCLC. As only a limited subset of NSCLC patien... read more here.
Keywords: nsclc; identifying cell; treatment; profiles associate ... See more keywords